ALX Oncology Holdings (ALXO) Net earnings per share growth forecast for next year

Symbol and logo of brand ALX Oncology Holdings (ALXO)

ALX Oncology Holdings (ALXO) is developing unique tumor evasion signal blockers, positioning itself for pricing power. The business relies on an independent product cycle, remaining a defensive asset regardless of macroeconomic conditions. The development of blocking proteins guarantees stable income through patents. The expected EPS growth for next year illustrates these prospects, where 2.30 shows the current value of the metric.

ALXO - ALX Oncology Earnings growth forecast for next year over the range 07/04/2022 - 11/18/2026

Metric breakdowns and analytics for ALX Oncology Holdings (ALXO)

Analysis of all company metrics:ALX Oncology Holdings
Core merchandise of ALX Oncology Holdings Inc.

For ALX Oncology (ALXO), whose operations are focused on costly R&D in cancer immunotherapy, consensus expectations for n+1 profit dynamics serve as an indicator of market optimism regarding the commercialization of its developments. This metric aggregates daily analyst forecasts for changes in net income for the coming year, measuring the trajectory of profitability. In the absence of operational cash flow, this data series assesses capital stability and the risk of depleting cash reserves.

Direct competitors

Net earnings per share growth forecast for next year immunitybio.com|Expected earnings per share growth for next year immunocore.com (IMCR)|Net earnings per share growth forecast for next year Janux Therapeutics Inc (JANX)|Expected earnings per share growth for next year Arcus Bio RCUS|Zymeworks Inc - Expected earnings per share growth for next year|Earnings growth forecast for next year Tango Therapeutics Corp TNGX|IOVA - Net earnings per share growth forecast for next year|IMTX (immatics.com) - Projected earnings per share growth rate for next year|Xencor Inc. (XNCR) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Compass Bio (CMPX)|Expected earnings per share growth for next year REPL|LYEL - Net earnings per one share growth forecast for next year|Expected earnings per share growth for next year IPHA (Innate Pharma, S.A.)|Projected earnings per share increase next year PYXS|Earnings growth forecast for next year CGEN (Compugen Ltd.)|Expected earnings per share trend next year IOBT|sutrobio.com - Earnings growth forecast for next year|Expected net earnings per share growth next year MiNK Therapeutics, Inc|Werewolf (HOWL) - Net earnings per share growth forecast for next year|Immix Biopharma Inc. - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Cue Biopharma|Earnings growth forecast for next year pdsbiotech.com|Net earnings per share growth forecast for next year sonnetbio.com (SONN)|MAIA: Net earnings per share change forecast for next year|Liminatus Pharma Inc. - Expected earnings per share growth for next year|LAVA Therapeutics N.V. (LVTX) - Expected net earnings per share growth next year|NXTC - Net earnings per share growth forecast for next year|LPTX: Net earnings per share growth forecast for next year|Intensity Therapeutics (INTS) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Sensei Bio (SNSE)|TOVX (Theriva Biologics Inc) - Earnings growth forecast for next year|Gritstone bio (GRTS) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year KA|Consensus forecast of earnings per share growth for next year NexImmune Inc|Net earnings per share growth forecast for next year turnstonebio.com TSBX|Consensus forecast of earnings per share growth for next year Vaccinex Inc (VCNX)|HARP - Net earnings per share growth forecast for next year